Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian oncology group for clinical research (G.O.I.R.C.)-Reference-Cited by-同舟云学术

Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian oncology group for clinical research (G.O.I.R.C.)

Published:1986-07 Issue:7 Volume:22 Page:761-764
ISSN:0277-5379
Container-title:European Journal of Cancer and Clinical Oncology
language:en
Short-container-title:European Journal of Cancer and Clinical Oncology

Author:

Cocconi Giorgio,Tonato Maurizio,di Costanzo Francesco,Bisagni Giancarlo,Belsanti Virginio,Buzzi Franco,Ceci Guido

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. A phase II trial of cis-dichlorodiammineplatinum II in breast and ovarian carcinomas;Bull,1978

2. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC1119875, CACP);Rossof;Cancer,1972

3. High dose cis-diamminedichloroplatinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity and therapeutic efficacy;Ostrow;Cancer Clin Trials,1980

4. Cis-diamminedichloroplatinum (CDDP) in advanced breast and colorectal carcinomas;Samal,1978

5. Phase II study of cis-dichlorodiammineplatinum (II) in advanced breast cancer;Yap;Cancer Treat Rep,1978

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment with Cisplatin and Etoposide Chemotherapy in Patient with Metastatic Breast Cancer;Journal of Breast Disease;2017-12-31

2. Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer;Chemotherapy;2011

3. The Renaissance of Platinum-Based Chemotherapy for Metastatic Breast Cancer;Journal of Chemotherapy;2008-10

4. Platinum-based Chemotherapy in Metastatic Breast Cancer: The Leicester (UK) Experience;Clinical Oncology;2005-06

5. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group;British Journal of Cancer;2005-02